全文获取类型
收费全文 | 288篇 |
免费 | 14篇 |
国内免费 | 2篇 |
专业分类
化学 | 163篇 |
晶体学 | 3篇 |
力学 | 5篇 |
数学 | 76篇 |
物理学 | 57篇 |
出版年
2023年 | 5篇 |
2022年 | 5篇 |
2021年 | 12篇 |
2020年 | 17篇 |
2019年 | 8篇 |
2018年 | 8篇 |
2017年 | 7篇 |
2016年 | 21篇 |
2015年 | 14篇 |
2014年 | 15篇 |
2013年 | 19篇 |
2012年 | 19篇 |
2011年 | 20篇 |
2010年 | 10篇 |
2009年 | 7篇 |
2008年 | 22篇 |
2007年 | 18篇 |
2006年 | 12篇 |
2005年 | 5篇 |
2004年 | 10篇 |
2003年 | 7篇 |
2002年 | 13篇 |
2001年 | 3篇 |
2000年 | 1篇 |
1998年 | 2篇 |
1996年 | 2篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1987年 | 1篇 |
1985年 | 2篇 |
1981年 | 1篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1966年 | 1篇 |
1914年 | 4篇 |
1883年 | 5篇 |
1882年 | 1篇 |
1881年 | 1篇 |
排序方式: 共有304条查询结果,搜索用时 389 毫秒
81.
The triblock poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) copolymers, Pluronics (L64, P65, and P123), form liquid crystalline (LC) mesophases with transition metal nitrate salts (TMS), [M(H(2)O)(n)](NO(3))(2), in the presence and absence of free water in the media. In this assembly process, M-OH(2) plays an important role as observed in a TMS:C(n)EO(m) (C(n)EO(m) is oligo(ethylene oxide) nonionic surfactants) system. The structure of the LC mesophases and interactions of the metal ion-nitrate ion and metal ion-Pluronic were investigated using microscopy (POM), diffraction (XRD), and spectroscopy (FTIR and micro-Raman) techniques. The TMS:L64 system requires a shear force for mesophase ordering to be observed using X-ray diffraction. However, TMS:P65 and TMS:P123 form well structured LC mesophases. Depending on the salt/Pluronic mole ratio, hexagonal LC mesophases are observed in the TMS:P65 systems and cubic and tetragonal LC mesophases in the TMS:P123 systems. The LC mesophase in the water/salt/Pluronic system is sensitive to the concentration of free (H(2)O) and coordinated water (M-OH(2)) molecules and demonstrates structural changes. As the free water is evaporated from the H(2)O:TMS:Pluronic LC mesophase (ternary mixture), the nitrate ion remains free in the media. However, complete evaporation of the free water molecules enforces the coordination of the nitrate ion to the metal ion in all TMS:Pluronic systems. 相似文献
82.
F. v. Fillinger J. Jolles K. Reicher E. H. Stein A. C. Andersen Ivar Bang Clarence E. May B. Oppler E. Herzfeld E. Salkowski Carl Neuberg Omer Schewket Alessandro Bernardi H. Schirokauer G. G. Wilenko A. W. Peters Lester Reed Harry Koenigsfeld O. Tunmann J. Amann 《Analytical and bioanalytical chemistry》1914,53(4-5):334-340
83.
84.
Arylated anthraquinones were prepared by Suzuki–Miyaura reactions of the bis(triflates) of various 1,3-(dihydroxy)anthraquinones. While the reactions of the bis(triflates) of parent 1,3-(dihydroxy)anthraquinone and of 2-chloro-1,3-di(hydroxy)anthraquinone proceeded with very good site-selectivity, the corresponding reactions of the bis(triflate) of 2-fluoro-1,3-diarylanthraquinones were not site-selective, which was explained based on the π-donating effect of the fluorine atom. 相似文献
85.
86.
87.
88.
89.
Soybean isoflavones possess hormonal and nonhormonal properties that may reduce the risk of coronary heart disease, osteoporosis, and certain cancers, and alleviate hot flashes in menopausal women. Among the various cancers whose risk may be reduced by isoflavones, there is particular interest in prostate cancer. Eleven trials have examined the effects of isoflavones on serum prostate-specific antigen (PSA) levels. The dose of isoflavones in these trials from supplements or soy protein ranged from 60 to 900 mg/day (typical Japanese intake is 30-50 mg/day), subject number/group ranged from 8 to 62, and study duration from 20 days to 1 year. Isoflavones did not affect serum PSA in healthy subjects. In contrast, in 4 of 8 trials involving prostate cancer patients, isoflavones significantly favorably affected PSA although in no studies was there an absolute decrease in PSA concentrations. The mechanism by which isoflavones affect PSA could not be determined from the existing research, although hormonal changes do not seem to be a factor. The clinical evidence is sufficiently encouraging to justify considering additional Phase II and III clinical trials investigating the efficacy of soy isoflavones in different populations of prostate cancer patients alone and in combination with other treatments. 相似文献
90.